Stock Market Reviews

ENGN (enGene Holdings Inc.) News

Get the latest news, insights, and market updates on ENGN (enGene Holdings Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
  BOSTON & MONTREAL, November 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET.
  Nov 25, 2025 - $ENGN
• enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results
  enGene Holdings Inc. recently reported additional positive preliminary data from its Phase 2 LEGEND trial, highlighting a 62% complete response rate at six months for detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The updated trial enrolled 125 patients, surpassing original targets, and enGene plans to file for regulatory approval in the second half of 2026 for this new gene therapy approach. We'll explore how these encouraging...
  Nov 13, 2025 - $ENGN
• enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
  BOSTON & MONTREAL, November 13, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commis
  Nov 13, 2025 - $ENGN
• enGene Announces Proposed Public Offering of Common Shares
  BOSTON & MONTREAL, November 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares sold
  Nov 12, 2025 - $ENGN
• enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial
  enGene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.
  Nov 11, 2025 - $ENGN
• Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
  Health care stocks were mixed pre-bell Tuesday, with the Health Care Select Sector SPDR Fund (XLV) u
  Nov 11, 2025 - $ENGN
• Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday as Investors Assess Impact of Government Shutdown
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr
  Nov 11, 2025 - $ENGN
• Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
  BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without conc
  Nov 11, 2025 - $ENGN
• enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
  BOSTON & MONTREAL, November 10, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-r
  Nov 10, 2025 - $ENGN
• enGene to Participate in Upcoming Investor Conferences
  BOSTON & MONTREAL, November 06, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:
  Nov 6, 2025 - $ENGN